Introduction: Despite many recent emerging therapeutic modalities that have prolonged the survival of melanoma patients, the prognosis of melanoma remains discouraging, and further understanding of the mechanisms underlying melanoma progression is needed. Melanoma patients often have multiple genetic mutations, with BRAF mutations being the most common. In this study, public databases were exploited to explore a potential therapeutic target for BRAF-mutated melanoma.Methods: In this study, we analyzed differentially expressed genes (DEGs) in normal tissues and melanomas, Braf wild-type and Braf mutant melanomas using information from TCGA databases and the GEO database. Subsequently, we analyzed the differential expression of CYTL1 in various tumor tissues and its effect on melanoma prognosis, and resolved the mutation status of CYTL1 and its related signalling pathways. By knocking down CYTL1 in melanoma cells, the effects of CYTL1 on melanoma cell proliferation, migration and invasion were further examined by CCK8 assay, Transwell assay and cell migration assay.Results: 24 overlapping genes were identified by analyzing DEGs common to melanoma and normal tissue, BRAF-mutated and BRAF wild-type melanoma. Among them, CYTL1 was highly expressed in melanoma, especially in BRAF-mutated melanoma, and the high expression of CYTL1 was associated with epithelial-mesenchymal transition (EMT), cell cycle, and cellular response to UV. In melanoma patients, especially BRAF-mutated melanoma patients, clinical studies showed a positive correlation between increased CYTL1 expression and shorter overall survival (OS) and disease-free survival (DFS). In vitro experiments further confirmed that the knockdown of CYTL1 significantly inhibited the migration and invasive ability of melanoma cells.Conclusion: CYTL1 is a valuable prognostic biomarker and a potentially effective therapeutic target in melanoma, especially BRAF-mutated melanoma.
To explore the effects of artificial sweeteners on reduced antibiotic susceptibility and expression of antibiotic resistance and virulence-related genes in bacteria exposed to permitted daily intake levels. We first evaluated the antibacterial effects of five commonly used artificial sweeteners (saccharin, cyclamate, aspartame, acesulfame potassium, and sucralose) on Escherichia coli and Bacillus subtilis, and detected changes in reactive oxygen species (ROS) production. We investigated the expression of genes associated with resistance, oxidative stress, and virulence using transcriptome sequencing after 2 h of exposure. The minimum inhibitory concentration (MIC) of artificial sweeteners for E. coli and B. subtilis were higher than the Codex Alimentarius Commission (CAC) defined daily intake limits. Except for saccharin, these sweeteners did not significantly affect the bacterial growth within 48 h. However, at these limiting concentrations, artificial sweeteners are associated with reduced antibiotic susceptibility and upregulation of resistance-related genes and enhance ROS production. Transcriptome analysis at 2 h revealed that artificial sweeteners upregulated genes associated with resistance, oxidative stress, and virulence compared to the glucose control. Additionally, we observed the effects of artificial sweeteners on iron uptake-related genes in E. coli, suggesting potential implications for bacterial ferroptosis that require further validation. Exposure to artificial sweeteners at CAC-permitted doses is associated with reduced antibiotic susceptibility and may affect bacterial function. Therefore, the safety of artificial sweeteners as substitutes for natural sugars requires careful consideration and further in vivo validation.